Geometry Dash APK Hill Climb Racing APK
29.6 F
New York
Friday, January 28, 2022

Adaptimmune Therapeutics (NASDAQ:ADAP) Soars 250% in May: What to do now

Must read

Medmen Enterprises Inc (OTCMKTS:MMNFF) Pulls Back From Highs as Buzz Cools Off

Among the sectors which have bounced back in 2021, the cannabis sector is one of considerable interest since it had been in...

VirtualArmour International Inc (OTCMKTS:VTLR) Jumps Another 250% This Week

Not every move in the stock market can always be explained and hence, investors are often rightly confused when a stock records...

Ozop Energy Solutions Inc (OZSC) is Riding a Green Wave of Momentum

Investors who are looking for fresh opportunities in rising stocks may have a lot to choose from at this point but it...

Drone Delivery Canada Corp (OTCMKTS:TAKOF) is Soaring after Roadmap Update

The drone industry has grown at a remarkable rate over the past five years or so and hence, it is no surprise...

The shares of biotech firm Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had a bit of a rollercoaster ride on Monday as the stock recorded a steep decline and then ended the day with significant gains. On Monday morning, the stock started things off in a pretty negative manner as it crashed by as much as 11%.

New Stock Offerings

The decline might have been brought about by Adaptimmune’s decision to make a public offering of as many as 12.5 million shares. However, it seems that positive news with regards to one of the company’s products under development triggered a rally, and the Adaptimmune stock ended the day with gains of as much as 19%.

This past Friday, the company revealed encouraging data with regards to its T-cell therapy platform, and that had resulted in a rally in the stock as well. It should be noted that the company had also presented the platform at the American Society for Clinical Oncology Annual Meeting. Adaptimmune revealed that the product was tested on patients suffering from synovial sarcoma, and the response rate stood at 50%. It is an impressive performance, and the rally in the stock was not a complete surprise.

The company currently commands a market cap of only $1.56 billion, and considering the fact that it has many more anti-cancer cell therapies in its pipeline, the valuation could prove to be a bargain. The company does not yet have any products on the market, but the data released on Friday for the product ADP A2M4 indicates that commercialization for the platform might not be too far away.

The company is currently engaged in signing up patients for the Spearhead 1 tests for the product, and that is going to be conducted at some point at the end of June. These are extremely vital times for Adaptimmune, and it could be worthwhile for investors to keep a close eye on the latest developments this month. Sign Up below for breakout alerts on $ADAP and other fast-moving stocks.

Latest article

iQSTEL Inc (OTCMKTS:IQST) Stock Makes a Big Move: Jumps 45% In a Week

In the past week, iQSTEL Inc (OTCMKTS: IQST) has emerged as a point of focus among a large number of investors and...

HUMBL Inc (OTCMKTS:HMBL) Stock Sees Big Bounce After Recent Slump

Since the beginning of 2021, HUMBL Inc (OTCMKTS:HMBL) had been one of the major movers from among penny stocks and had come into...

Dividend Stocks to Buy Now

A classic mistake that investors make when looking for dividend stocks is to just go for the biggest dividend yield. It makes...

88 Energy Ltd (OTCMKTS:EEENF) Stock Surges 40% But Can’t Hold Gains

The oil and gas company 88 Energy Ltd (OTCMKTS:EEENF) seems to have come back on to the radars of investors over the...

Net Savings Link Inc (OTCMKTS:NSAV) Stock is Getting Pummeled Again

Nowadays there are plenty of options for investors when it comes to making investments in the cryptocurrency and...
Şehirler arası nakliyat ve Şehirler arası taşımacılık konusunda en uygun fiyatlar ve en kaliteli hizmet.
ofis taşıma firmaları ve ofis taşıma konusunda en uygun fiyatlar ve en kaliteli hizmet. Affordable best sms verification service